Literature DB >> 16177884

Pharmacokinetic and behavioral effects of allopregnanolone in healthy women.

Erika Timby1, Matts Balgård, Sigrid Nyberg, Olav Spigset, Agneta Andersson, Joanna Porankiewicz-Asplund, Robert H Purdy, Di Zhu, Torbjörn Bäckström, Inger Sundström Poromaa.   

Abstract

RATIONALE: The behavioral effects of allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one) in women are not known.
OBJECTIVE: Allopregnanolone, a neuroactive steroid secreted by the mammalian ovary, exerts its anesthetic, anxiolytic, and sedative/hypnotic effects through potentiation of GABAA receptors. The purpose of this study was to evaluate the behavioral effects of allopregnanolone in healthy women.
METHODS: Ten healthy women were given three increasing intravenous doses of allopregnanolone in the follicular phase of the menstrual cycle. Saccadic eye movement parameters and visual analogue scales of sedation were used to evaluate the behavioral response of allopregnanolone. Repeated blood samples for analyses of allopregnanolone were drawn throughout the study day.
RESULTS: Exogenously administered allopregnanolone decreases saccadic eye movement parameters and increases subjective ratings of sedation that correlate with increased serum concentrations of this neuroactive steroid.
CONCLUSION: The behavioral effects of allopregnanolone are similar to that of its 5beta-stereoisomer, pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one). Apart from fatigue and mild nausea, allopregnanolone given in a cumulative dose of 0.09 mg/kg did not have any adverse effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177884     DOI: 10.1007/s00213-005-0148-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  70 in total

1.  Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review.

Authors:  K Wyatt; P Dimmock; P Jones; M Obhrai; S O'Brien
Journal:  BMJ       Date:  2001-10-06

2.  The human corpus luteum secretes 5 alpha-pregnane-3,20-dione.

Authors:  T Bäckström; A Andersson; D T Baird; G Selstam
Journal:  Acta Endocrinol (Copenh)       Date:  1986-01

3.  Physiological aspects of steroids with anaesthetic properties.

Authors:  M Holzbauer
Journal:  Med Biol       Date:  1976-08

4.  Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics.

Authors:  I Sundström; O Spigset; A Andersson; P Appelblad; T Bäckström
Journal:  Eur J Clin Pharmacol       Date:  1999-04       Impact factor: 2.953

5.  Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat.

Authors:  M Gulinello; Q H Gong; X Li; S S Smith
Journal:  Brain Res       Date:  2001-08-10       Impact factor: 3.252

6.  Determination of progesterone and some of its neuroactive ring A-reduced metabolites in human serum.

Authors:  B E Pearson Murphy; C M Allison
Journal:  J Steroid Biochem Mol Biol       Date:  2000-10       Impact factor: 4.292

7.  Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects.

Authors:  I Sundström; A Andersson; S Nyberg; D Ashbrook; R H Purdy; T Bäckström
Journal:  Neuroendocrinology       Date:  1998-02       Impact factor: 4.914

8.  Dynamic aspects of acute tolerance to allopregnanolone evaluated using anaesthesia threshold in male rats.

Authors:  D Zhu; V Birzniece; T Bäckström; G Wahlström
Journal:  Br J Anaesth       Date:  2004-07-26       Impact factor: 9.166

9.  Effects of antidepressant treatment on neuroactive steroids in major depression.

Authors:  E Romeo; A Ströhle; G Spalletta; F di Michele; B Hermann; F Holsboer; A Pasini; R Rupprecht
Journal:  Am J Psychiatry       Date:  1998-07       Impact factor: 18.112

10.  Pharmacokinetics and pharmacodynamics of eltanolone (pregnanolone), a new steroid intravenous anaesthetic, in humans.

Authors:  P Carl; S Høgskilde; T Lang-Jensen; V Bach; J Jacobsen; M B Sørensen; M Grälls; L Widlund
Journal:  Acta Anaesthesiol Scand       Date:  1994-10       Impact factor: 2.105

View more
  36 in total

1.  Pediatric super-refractory status epilepticus treated with allopregnanolone.

Authors:  Eileen Broomall; JoAnne E Natale; Michele Grimason; Joshua Goldstein; Craig M Smith; Celia Chang; Stephen Kanes; Michael A Rogawski; Mark S Wainwright
Journal:  Ann Neurol       Date:  2014-11-11       Impact factor: 10.422

2.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Roux-en-Y Gastric Bypass Surgery in Patients with Polycystic Ovary Syndrome and Metabolic Syndrome.

Authors:  Sahruh Turkmen; Alebtekin Ahangari; Torbjörn Bäckstrom
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

4.  A randomized controlled trial of ganaxolone in posttraumatic stress disorder.

Authors:  Ann M Rasmusson; Christine E Marx; Sonia Jain; Gail M Farfel; Julia Tsai; Xiaoying Sun; Thomas D Geracioti; Mark B Hamner; James Lohr; Richard Rosse; Lanier Summerall; Jennifer C Naylor; Cristine Cusin; Ariel J Lang; Rema Raman; Murray B Stein
Journal:  Psychopharmacology (Berl)       Date:  2017-07-01       Impact factor: 4.530

5.  Women with PTSD have a changed sensitivity to GABA-A receptor active substances.

Authors:  Anna Tiihonen Möller; Torbjörn Bäckström; Sigrid Nyberg; Hans Peter Söndergaard; Lotti Helström
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

6.  Development and validation of an LC-MS/MS assay for the quantification of allopregnanolone and its progesterone-derived isomers, precursors, and cortisol/cortisone in pregnancy.

Authors:  G Mayne; E De Bloois; D Dabelea; U Christians
Journal:  Anal Bioanal Chem       Date:  2021-07-19       Impact factor: 4.142

Review 7.  Neuroactive steroids for the treatment of status epilepticus.

Authors:  Michael A Rogawski; Carlos M Loya; Kiran Reddy; Dorota Zolkowska; Christoph Lossin
Journal:  Epilepsia       Date:  2013-09       Impact factor: 5.864

8.  Differences in the reinstatement of ethanol seeking with ganaxolone and gaboxadol.

Authors:  M J Ramaker; M M Ford; T J Phillips; D A Finn
Journal:  Neuroscience       Date:  2014-05-09       Impact factor: 3.590

9.  Luteal serum BDNF and HSP70 levels in women with premenstrual dysphoric disorder.

Authors:  E Oral; H Ozcan; T S Kirkan; S Askin; M Gulec; N Aydin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-03-02       Impact factor: 5.270

10.  5α-reduced progestogens ameliorate mood-related behavioral pathology, neurotoxicity, and microgliosis associated with exposure to HIV-1 Tat.

Authors:  Jason J Paris; ShiPing Zou; Yun K Hahn; Pamela E Knapp; Kurt F Hauser
Journal:  Brain Behav Immun       Date:  2016-01-13       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.